PortalPublikationenSalvage therapy with high-dose cytarabine and mitoxantrone i...

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy

Standard

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. / Hütter-Krönke, Marie-Luise; Benner, Axel; Döhner, Konstanze; Krauter, Jürgen; Weber, Daniela; Moessner, Margit; Köhne, Claus-Henning; Horst, Heinz A; Schmidt-Wolf, Ingo G H; Rummel, Mathias; Götze, Katharina; Koller, Elisabeth; Petzer, Andreas L; Salwender, Hans; Fiedler, Walter; Kirchen, Heinz; Haase, Detlef; Kremers, Stephan; Theobald, Matthias; Matzdorff, Axel C; Ganser, Arnold; Döhner, Hartmut; Schlenk, Richard F.

in: HAEMATOLOGICA, Jahrgang 101, Nr. 7, 07.2016, S. 839-45.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hütter-Krönke, M-L, Benner, A, Döhner, K, Krauter, J, Weber, D, Moessner, M, Köhne, C-H, Horst, HA, Schmidt-Wolf, IGH, Rummel, M, Götze, K, Koller, E, Petzer, AL, Salwender, H, Fiedler, W, Kirchen, H, Haase, D, Kremers, S, Theobald, M, Matzdorff, AC, Ganser, A, Döhner, H & Schlenk, RF 2016, 'Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy', HAEMATOLOGICA, Jg. 101, Nr. 7, S. 839-45. https://doi.org/10.3324/haematol.2015.141622

APA

Hütter-Krönke, M-L., Benner, A., Döhner, K., Krauter, J., Weber, D., Moessner, M., Köhne, C-H., Horst, H. A., Schmidt-Wolf, I. G. H., Rummel, M., Götze, K., Koller, E., Petzer, A. L., Salwender, H., Fiedler, W., Kirchen, H., Haase, D., Kremers, S., Theobald, M., ... Schlenk, R. F. (2016). Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. HAEMATOLOGICA, 101(7), 839-45. https://doi.org/10.3324/haematol.2015.141622

Vancouver

Hütter-Krönke M-L, Benner A, Döhner K, Krauter J, Weber D, Moessner M et al. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. HAEMATOLOGICA. 2016 Jul;101(7):839-45. https://doi.org/10.3324/haematol.2015.141622

Bibtex

@article{b4e98fe086784f1f80b1055cb7559bf9,
title = "Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy",
abstract = "Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3mg/m2; intravenously on day 1), all-trans retinoic acid (45 mg/m2; per orally on days 4-6 and 15 mg/m2; orally on days 7-28), high-dose cytarabine (3 g/m2/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m2 intravenously on days 2-3) in 93 patients aged 18 to 60 years refractory to one cycle of induction therapy. Primary endpoint of the study was response to therapy; secondary endpoints included evaluation of toxicities, in particular rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51%) and partial remission in 10 (11%) patients resulting in an overall response rate of 61.5%; 33 (35.5%) patients had refractory disease and 3 patients (3%) died. Allogeneic hematopoietic cell transplantation was performed in 71 (76%) patients; 6 of the 71 (8.5%) patients developed moderate or severe sinusoidal obstruction syndrome after transplantation. Four-year overall survival rate was 32% (95%-confidence interval 24%-43%). Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation (n=51) had a 4-year survival rate of 49% (95%-confidence intervaI, 37%-64%). Patients with fms-like tyrosine kinase internal tandem duplication positive acute myeloid leukemia had a poor outcome despite transplantation. In conclusion, the described regimen is an effective and tolerable salvage therapy for patients who are primary refractory to one cycle of conventional intensive induction therapy. (ClinicalTrials.gov,NCT00143975).",
author = "Marie-Luise H{\"u}tter-Kr{\"o}nke and Axel Benner and Konstanze D{\"o}hner and J{\"u}rgen Krauter and Daniela Weber and Margit Moessner and Claus-Henning K{\"o}hne and Horst, {Heinz A} and Schmidt-Wolf, {Ingo G H} and Mathias Rummel and Katharina G{\"o}tze and Elisabeth Koller and Petzer, {Andreas L} and Hans Salwender and Walter Fiedler and Heinz Kirchen and Detlef Haase and Stephan Kremers and Matthias Theobald and Matzdorff, {Axel C} and Arnold Ganser and Hartmut D{\"o}hner and Schlenk, {Richard F}",
note = "Copyright {\textcopyright} 2016, Ferrata Storti Foundation.",
year = "2016",
month = jul,
doi = "10.3324/haematol.2015.141622",
language = "English",
volume = "101",
pages = "839--45",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

RIS

TY - JOUR

T1 - Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy

AU - Hütter-Krönke, Marie-Luise

AU - Benner, Axel

AU - Döhner, Konstanze

AU - Krauter, Jürgen

AU - Weber, Daniela

AU - Moessner, Margit

AU - Köhne, Claus-Henning

AU - Horst, Heinz A

AU - Schmidt-Wolf, Ingo G H

AU - Rummel, Mathias

AU - Götze, Katharina

AU - Koller, Elisabeth

AU - Petzer, Andreas L

AU - Salwender, Hans

AU - Fiedler, Walter

AU - Kirchen, Heinz

AU - Haase, Detlef

AU - Kremers, Stephan

AU - Theobald, Matthias

AU - Matzdorff, Axel C

AU - Ganser, Arnold

AU - Döhner, Hartmut

AU - Schlenk, Richard F

N1 - Copyright © 2016, Ferrata Storti Foundation.

PY - 2016/7

Y1 - 2016/7

N2 - Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3mg/m2; intravenously on day 1), all-trans retinoic acid (45 mg/m2; per orally on days 4-6 and 15 mg/m2; orally on days 7-28), high-dose cytarabine (3 g/m2/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m2 intravenously on days 2-3) in 93 patients aged 18 to 60 years refractory to one cycle of induction therapy. Primary endpoint of the study was response to therapy; secondary endpoints included evaluation of toxicities, in particular rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51%) and partial remission in 10 (11%) patients resulting in an overall response rate of 61.5%; 33 (35.5%) patients had refractory disease and 3 patients (3%) died. Allogeneic hematopoietic cell transplantation was performed in 71 (76%) patients; 6 of the 71 (8.5%) patients developed moderate or severe sinusoidal obstruction syndrome after transplantation. Four-year overall survival rate was 32% (95%-confidence interval 24%-43%). Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation (n=51) had a 4-year survival rate of 49% (95%-confidence intervaI, 37%-64%). Patients with fms-like tyrosine kinase internal tandem duplication positive acute myeloid leukemia had a poor outcome despite transplantation. In conclusion, the described regimen is an effective and tolerable salvage therapy for patients who are primary refractory to one cycle of conventional intensive induction therapy. (ClinicalTrials.gov,NCT00143975).

AB - Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3mg/m2; intravenously on day 1), all-trans retinoic acid (45 mg/m2; per orally on days 4-6 and 15 mg/m2; orally on days 7-28), high-dose cytarabine (3 g/m2/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m2 intravenously on days 2-3) in 93 patients aged 18 to 60 years refractory to one cycle of induction therapy. Primary endpoint of the study was response to therapy; secondary endpoints included evaluation of toxicities, in particular rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51%) and partial remission in 10 (11%) patients resulting in an overall response rate of 61.5%; 33 (35.5%) patients had refractory disease and 3 patients (3%) died. Allogeneic hematopoietic cell transplantation was performed in 71 (76%) patients; 6 of the 71 (8.5%) patients developed moderate or severe sinusoidal obstruction syndrome after transplantation. Four-year overall survival rate was 32% (95%-confidence interval 24%-43%). Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation (n=51) had a 4-year survival rate of 49% (95%-confidence intervaI, 37%-64%). Patients with fms-like tyrosine kinase internal tandem duplication positive acute myeloid leukemia had a poor outcome despite transplantation. In conclusion, the described regimen is an effective and tolerable salvage therapy for patients who are primary refractory to one cycle of conventional intensive induction therapy. (ClinicalTrials.gov,NCT00143975).

U2 - 10.3324/haematol.2015.141622

DO - 10.3324/haematol.2015.141622

M3 - SCORING: Journal article

C2 - 27036160

VL - 101

SP - 839

EP - 845

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 7

ER -